Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms
A little less than a week before AstraZeneca’s takeover of Alexion is expected to be completed, the rare disease biotech offered up a cut of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
